SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
SI-BONE, Inc. received FDA 510(k) clearance for its iFuse TORQ TNT implant system, designed for pelvic fragility fractures. TNT offers improved treatment over current standards, featuring anatomy-specific design for early fixation and reduced screw backout. The global sacroiliac joint fusion market, valued at $721.2 million in 2023, is expected to grow, supported by technological advancements and increasing prevalence of related conditions.
Reference News
SI-BONE, Inc. received FDA 510(k) clearance for its iFuse TORQ TNT implant system, designed for pelvic fragility fractures. TNT offers improved treatment over current standards, featuring anatomy-specific design for early fixation and reduced screw backout. The global sacroiliac joint fusion market, valued at $721.2 million in 2023, is expected to grow, supported by technological advancements and increasing prevalence of related conditions.